TY - JOUR
T1 - Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance
AU - Hung, Yi Jen
AU - Hsieh, Chang Hsun
AU - Pei, Dee
AU - Kuo, Shi Wen
AU - Lee, Jiunn Tay
AU - Wu, Ling Yi
AU - He, Chih Tsueng
AU - Lee, Chien Hsing
AU - Fan, Sandra Chyi
AU - Sheu, Wayne Huey Herng
PY - 2005/1
Y1 - 2005/1
N2 - Objective: This study was designed to evaluate the effects of rosiglitazone (ROS) on insulin sensitivity, β-cell function, and glycaemic response to glucose challenge and meal in subjects with impaired glucose tolerance (IGT). Methods: Thirty patients with IGT (ages between 30 and 75 years and BMI (body mass index) ≤ 27 kg/m2) were randomly assigned to receive either placebo (n = 15) or ROS (4 mg/day) (n = 15). All participants underwent a 75-g oral glucose tolerance test (OGTT), meal test, and frequently sampled intravenous glucose tolerance test (FSIGT) before and after the 12-week treatment. Results: After 12 weeks of ROS treatment, there were significant increases in total cholesterol (TC) (4·25 ± 0·22 vs 4·80 ± 0·17 mmol/l, P < 0·001), high-density lipoprotein cholesterol (HDL-C) (1·25 ± 0·07 vs 1·43 ± 0·06 mmol/l, P < 0·05), and low-density lipoprotein cholesterol (LDL-C) (2·70 ± 0·15 vs 3·37 ± 0·17 mmol/l, P < 0·05) without changes in triglyceride concentration, TC/HDL-C and LDL-C/HDL-C ratio. Although the acute insulin response (AIR) to intravenous glucose and disposition index (measured as the ability of pancreatic β-cell compensation in the presence of insulin resistance) remained unchanged, the insulin sensitivity (SI) and glucose effectiveness (SG) were remarkably elevated (0·38 ± 0·06 vs 0·54 ± 0·09 × 10-5 min-1 /pmol, P < 0·05; 0·017 ± 0·002 vs 0·021 ± 0·001 min-1, P < 0·05, respectively) in the ROS group. The glucose, insulin, and c-peptide areas under curve (AUC) in response to OGTT and the glucose and insulin AUC during meal were significantly ameliorated in the ROS group. Five out of 15 (33%) and two out of 15 (13%) subjects treated with ROS and placebo, respectively, reversed to normal response during OGTT (P < 0·05). Conclusion: Rosiglitazone treatment significantly improved insulin resistance and reduced postchallenge glucose and insulin concentrations in patients with impaired glucose tolerance without remarkable effects on β-cell secretory function.
AB - Objective: This study was designed to evaluate the effects of rosiglitazone (ROS) on insulin sensitivity, β-cell function, and glycaemic response to glucose challenge and meal in subjects with impaired glucose tolerance (IGT). Methods: Thirty patients with IGT (ages between 30 and 75 years and BMI (body mass index) ≤ 27 kg/m2) were randomly assigned to receive either placebo (n = 15) or ROS (4 mg/day) (n = 15). All participants underwent a 75-g oral glucose tolerance test (OGTT), meal test, and frequently sampled intravenous glucose tolerance test (FSIGT) before and after the 12-week treatment. Results: After 12 weeks of ROS treatment, there were significant increases in total cholesterol (TC) (4·25 ± 0·22 vs 4·80 ± 0·17 mmol/l, P < 0·001), high-density lipoprotein cholesterol (HDL-C) (1·25 ± 0·07 vs 1·43 ± 0·06 mmol/l, P < 0·05), and low-density lipoprotein cholesterol (LDL-C) (2·70 ± 0·15 vs 3·37 ± 0·17 mmol/l, P < 0·05) without changes in triglyceride concentration, TC/HDL-C and LDL-C/HDL-C ratio. Although the acute insulin response (AIR) to intravenous glucose and disposition index (measured as the ability of pancreatic β-cell compensation in the presence of insulin resistance) remained unchanged, the insulin sensitivity (SI) and glucose effectiveness (SG) were remarkably elevated (0·38 ± 0·06 vs 0·54 ± 0·09 × 10-5 min-1 /pmol, P < 0·05; 0·017 ± 0·002 vs 0·021 ± 0·001 min-1, P < 0·05, respectively) in the ROS group. The glucose, insulin, and c-peptide areas under curve (AUC) in response to OGTT and the glucose and insulin AUC during meal were significantly ameliorated in the ROS group. Five out of 15 (33%) and two out of 15 (13%) subjects treated with ROS and placebo, respectively, reversed to normal response during OGTT (P < 0·05). Conclusion: Rosiglitazone treatment significantly improved insulin resistance and reduced postchallenge glucose and insulin concentrations in patients with impaired glucose tolerance without remarkable effects on β-cell secretory function.
UR - http://www.scopus.com/inward/record.url?scp=19944433634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944433634&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2265.2004.02178.x
DO - 10.1111/j.1365-2265.2004.02178.x
M3 - Article
C2 - 15638875
AN - SCOPUS:19944433634
SN - 0300-0664
VL - 62
SP - 85
EP - 91
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 1
ER -
